Published in Biotech Business Week, January 1st, 2007
The revenue growth resulted from increased demand from the global public sector. Net income attributable to common shareholders was $52,105 or zero cents per diluted share versus a net loss of $136,896, or 1-cent loss per diluted share for the 3 months ended September 30, 2005.
For the year ended September 30, 2006, the company reported total revenues of $14,824,242 compared with revenues of $11,161,555 for the prior...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.